Semaglutide: Difference between revisions
From Proteopedia
Jump to navigationJump to search
m Ozempit moved to Semaglutide |
No edit summary |
||
| Line 170: | Line 170: | ||
[[Image:Semaglutide side effects.png|600px]] | [[Image:Semaglutide side effects.png|600px]] | ||
The bar chart depicts the proportion of patients experiencing common adverse events (AEs) during Phase 3a trials for semaglutide (0.5 mg and 1.0 mg) compared to other treatments, including exenatide ER and insulin glargine. The AEs include gastrointestinal disorders (nausea, vomiting, diarrhea, constipation), nasopharyngitis, fatigue, and headache. Data are presented as adjusted percentages, with odds ratios (OR) and confidence intervals (CI) providing additional context. OR values above 1.0 suggest a higher likelihood of AEs with semaglutide, while CIs indicate the range of variability and precision. The results show that semaglutide, particularly at the 1.0 mg dose, is associated with a higher frequency of gastrointestinal AEs compared to comparators. Neurological side effects, such as headache and fatigue, and nasopharyngitis were also more common in semaglutide groups. These findings underscore the dose-dependent nature of AEs with semaglutide and the importance of balancing its efficacy in weight loss with patient tolerability.<ref name="euro"/> | The bar chart depicts the proportion of patients experiencing common adverse events (AEs) during Phase 3a trials for semaglutide (0.5 mg and 1.0 mg) compared to other treatments, including exenatide ER and insulin glargine. The AEs include gastrointestinal disorders (nausea, vomiting, diarrhea, constipation), nasopharyngitis, fatigue, and headache. Data are presented as adjusted percentages, with odds ratios (OR) and confidence intervals (CI) providing additional context. OR values above 1.0 suggest a higher likelihood of AEs with semaglutide, while CIs indicate the range of variability and precision. The results show that semaglutide, particularly at the 1.0 mg dose, is associated with a higher frequency of gastrointestinal AEs compared to comparators. Neurological side effects, such as headache and fatigue, and nasopharyngitis were also more common in semaglutide groups. These findings underscore the dose-dependent nature of AEs with semaglutide and the importance of balancing its efficacy in weight loss with patient tolerability.<ref name="euro"/> | ||
| Line 182: | Line 183: | ||
==Student contributors== | ==Student contributors== | ||
This page was created as a two-week project of an undergraduate biochemistry course. Karsten Theis would like to acknowledge contributors to the Structure, Half-life and Side effects sections, Paige, Marissa, Faith McCormack, | This page was created as a two-week project of an undergraduate biochemistry course. Karsten Theis would like to acknowledge contributors to the Structure, Half-life and Side effects sections, Paige, Marissa, Faith McCormack, William Buckley, Humzah, Mahrosha, Evelyn, Naba Algertani, Faiza, Sara, and Natalisha. | ||
== References == | == References == | ||
<references/> | <references/> | ||
